Technical Analysis for RDUS - Radius Health, Inc.

Grade Last Price % Change Price Change
grade F 10.86 -3.89% -0.44
RDUS closed down 4.07 percent on Wednesday, September 23, 2020, on approximately normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical RDUS trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -3.89%
MACD Bearish Signal Line Cross Bearish -3.89%
Outside Day Range Expansion -3.89%
Fell Below 20 DMA Bearish -6.90%
Bearish Engulfing Bearish -9.80%
Fell Below 50 DMA Bearish -9.80%
20 DMA Support Bullish -9.80%
Upper Bollinger Band Touch Strength -9.80%
Shooting Star Candlestick Bearish -13.47%
50 DMA Support Bullish -13.47%
Older End-of-Day Gignals for RDUS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
2x Volume Pace about 6 hours ago
Down 5% about 6 hours ago
1.5x Volume Pace about 7 hours ago
Down 3% about 7 hours ago
Down 2 % about 7 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Radius Health, Inc., a biopharmaceutical company, focuses on developing novel therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. Its lead product includes abaloparatide (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein, which is in Phase III clinical development for the treatment of osteoporosis. The company is also developing RAD1901, a selective estrogen receptor down-regulator/degrader for the treatment of breast cancer brain metastases, and vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator, which is in preclinical development stage for the treatment of weight loss due to cancer cachexia, muscle frailty and osteoporosis, and breast cancer. It has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M; Ipsen Pharma SAS; Eisai; Lonza Group Ltd.; and Charles River Laboratories, Inc. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Biopharmaceutical Cancer Drugs Breast Cancer Endocrine System Hormones Osteoporosis Amines Treatment Of Breast Cancer Antiestrogens Eisai Selective Estrogen Receptor Modulators

Is RDUS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 29.89
52 Week Low 10.32
Average Volume 626,700
200-Day Moving Average 15.27
50-Day Moving Average 12.26
20-Day Moving Average 11.98
10-Day Moving Average 11.89
Average True Range 0.66
ADX 12.81
+DI 19.17
-DI 22.91
Chandelier Exit (Long, 3 ATRs ) 11.02
Chandelier Exit (Short, 3 ATRs ) 13.00
Upper Bollinger Band 12.73
Lower Bollinger Band 11.23
Percent B (%b) 0.05
BandWidth 12.59
MACD Line -0.14
MACD Signal Line -0.11
MACD Histogram -0.0228
Fundamentals Value
Market Cap 490.25 Million
Num Shares 43.4 Million
EPS -5.19
Price-to-Earnings (P/E) Ratio -2.18
Price-to-Sales 1353.51
Price-to-Book 6.40
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.35
Resistance 3 (R3) 12.46 12.22 12.18
Resistance 2 (R2) 12.22 11.95 12.17 12.12
Resistance 1 (R1) 11.76 11.79 11.64 11.65 12.06
Pivot Point 11.52 11.52 11.46 11.47 11.52
Support 1 (S1) 11.06 11.25 10.94 10.95 10.54
Support 2 (S2) 10.82 11.09 10.77 10.48
Support 3 (S3) 10.36 10.82 10.43
Support 4 (S4) 10.25